FibroGen, Inc.
FGEN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $3 | -$123 |
| % Growth | -20.2% | -50.8% | 102.2% | – |
| Cost of Goods Sold | -$0 | $0 | $0 | -$21 |
| Gross Profit | $1 | $1 | $2 | -$103 |
| % Margin | 105.4% | 93.7% | 90.8% | 83.2% |
| R&D Expenses | $1 | $6 | $9 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5 | $7 | $8 | -$13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $7 | $13 | $17 | -$11 |
| Operating Income | -$5 | -$12 | -$15 | -$92 |
| % Margin | -502.9% | -894.1% | -544.7% | 74.4% |
| Other Income/Exp. Net | -$8 | -$2 | -$2 | $4 |
| Pre-Tax Income | -$13 | -$14 | -$17 | -$88 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | $201 | -$8 | $5 | $18 |
| % Margin | 18,646.5% | -564% | 169.4% | -14.6% |
| EPS | 49.61 | -1.88 | 0.05 | 4.5 |
| % Growth | 2,738.8% | -3,860% | -98.9% | – |
| EPS Diluted | 49.61 | -1.88 | 0.05 | 4.5 |
| Weighted Avg Shares Out | 4 | 4 | 101 | 4 |
| Weighted Avg Shares Out Dil | 4 | 4 | 101 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $2 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$12 | -$14 | -$91 |
| % Margin | -1,010.3% | -856.5% | -517.7% | 73.9% |